These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 31038541)

  • 1. Candesartan inhibits inflammation through an angiotensin II type 1 receptor independent way in human embryonic kidney epithelial cells.
    Yu Y; Jiang H; Niu Y; Zhang X; Zhang Y; Liu XI; Qi T; Yu C
    An Acad Bras Cienc; 2019; 91(2):e20180699. PubMed ID: 31038541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candesartan reduces the innate immune response to lipopolysaccharide in human monocytes.
    Larrayoz IM; Pang T; Benicky J; Pavel J; Sánchez-Lemus E; Saavedra JM
    J Hypertens; 2009 Dec; 27(12):2365-76. PubMed ID: 19730394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candesartan inhibits LPS-induced expression increase of toll-like receptor 4 and downstream inflammatory factors likely via angiotensin II type 1 receptor independent pathway in human renal tubular epithelial cells.
    Zhao LQ; Huang JL; Yu Y; Lu Y; Fu LJ; Wang JL; Wang YD; Yu C
    Sheng Li Xue Bao; 2013 Dec; 65(6):623-30. PubMed ID: 24343720
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade.
    Chen S; Ge Y; Si J; Rifai A; Dworkin LD; Gong R
    Kidney Int; 2008 Nov; 74(9):1128-38. PubMed ID: 18650791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible roles of tumor necrosis factor-α and angiotensin II type 1 receptor on high glucose-induced damage in renal proximal tubular cells.
    Takao T; Horino T; Matsumoto R; Shimamura Y; Ogata K; Inoue K; Taniguchi Y; Taguchi T; Terada Y
    Ren Fail; 2015 Feb; 37(1):160-4. PubMed ID: 25222109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective mechanisms of the angiotensin II type 1 receptor blocker candesartan against cerebral ischemia: in-vivo and in-vitro studies.
    Liu H; Kitazato KT; Uno M; Yagi K; Kanematsu Y; Tamura T; Tada Y; Kinouchi T; Nagahiro S
    J Hypertens; 2008 Jul; 26(7):1435-45. PubMed ID: 18551021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Angiotensin type-1 receptor blocker candesartan inhibits calcium oxalate crystal deposition in ethylene glycol-treated rat kidneys.
    Yoshioka I; Tsujihata M; Akanae W; Nonomura N; Okuyama A
    Urology; 2011 Apr; 77(4):1007.e9-1007.e14. PubMed ID: 21256551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroprotection against retinal ischemia-reperfusion injury by blocking the angiotensin II type 1 receptor.
    Fukuda K; Hirooka K; Mizote M; Nakamura T; Itano T; Shiraga F
    Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3629-38. PubMed ID: 20164447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin II receptor blocker inhibits tumour necrosis factor-alpha-induced cell damage in human renal proximal tubular epithelial cells.
    Kagawa T; Takao T; Horino T; Matsumoto R; Inoue K; Morita T; Hashimoto K
    Nephrology (Carlton); 2008 Jun; 13(4):309-15. PubMed ID: 18331441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II stimulates the release of interleukin-6 and interleukin-8 from cultured human adipocytes by activation of NF-kappaB.
    Skurk T; van Harmelen V; Hauner H
    Arterioscler Thromb Vasc Biol; 2004 Jul; 24(7):1199-203. PubMed ID: 15130920
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The angiotensin II type 1 receptor blocker candesartan suppresses proliferation and fibrosis in gastric cancer.
    Okazaki M; Fushida S; Harada S; Tsukada T; Kinoshita J; Oyama K; Tajima H; Ninomiya I; Fujimura T; Ohta T
    Cancer Lett; 2014 Dec; 355(1):46-53. PubMed ID: 25224569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Candesartan improves memory decline in mice: involvement of AT1 receptors in memory deficit induced by intracerebral streptozotocin.
    Tota S; Kamat PK; Awasthi H; Singh N; Raghubir R; Nath C; Hanif K
    Behav Brain Res; 2009 May; 199(2):235-40. PubMed ID: 19103228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective effects of angiotensin II type 1 receptor (AT1-R) blocker via modulating AT1-R signaling and decreased extracellular glutamate levels.
    Fujita T; Hirooka K; Nakamura T; Itano T; Nishiyama A; Nagai Y; Shiraga F
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):4099-110. PubMed ID: 22661470
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of angiotensin on the expression of fibrosis-associated cytokines, growth factors, and matrix proteins in human lung fibroblasts.
    Okada M; Suzuki K; Matsumoto M; Takada K; Nakanishi T; Horikoshi H; Higuchi T; Hosono Y; Nakayama M; Ohsuzu F
    J Clin Pharm Ther; 2009 Jun; 34(3):288-99. PubMed ID: 19650251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of candesartan on human AT1 receptor-expressing Chinese hamster ovary cells.
    Vauquelin G; Fierens FL; De Backer JP; Vanderheyden PM
    J Am Soc Nephrol; 1999 Jan; 10 Suppl 11():S15-7. PubMed ID: 9892135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiotensin II AT1 blockade reduces the lipopolysaccharide-induced innate immune response in rat spleen.
    Sánchez-Lemus E; Benicky J; Pavel J; Larrayoz IM; Zhou J; Baliova M; Nishioku T; Saavedra JM
    Am J Physiol Regul Integr Comp Physiol; 2009 May; 296(5):R1376-84. PubMed ID: 19225144
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin II AT1 receptor blockade decreases lipopolysaccharide-induced inflammation in the rat adrenal gland.
    Sanchez-Lemus E; Murakami Y; Larrayoz-Roldan IM; Moughamian AJ; Pavel J; Nishioku T; Saavedra JM
    Endocrinology; 2008 Oct; 149(10):5177-88. PubMed ID: 18556352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic NF-κB blockade improves renal angiotensin II type 1 receptor functions and reduces blood pressure in Zucker diabetic rats.
    Luo H; Wang X; Wang J; Chen C; Wang N; Xu Z; Chen S; Zeng C
    Cardiovasc Diabetol; 2015 Jun; 14():76. PubMed ID: 26055622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AT1 receptor antagonism is proangiogenic in the brain: BDNF a novel mediator.
    Alhusban A; Kozak A; Ergul A; Fagan SC
    J Pharmacol Exp Ther; 2013 Feb; 344(2):348-59. PubMed ID: 23211364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential effects of losartan and candesartan on vasoconstrictor responses in the rat.
    Nossaman BD; Baber SR; Nazim MM; Detrolio JD; Kadowitz PJ
    Can J Physiol Pharmacol; 2007; 85(3-4):360-71. PubMed ID: 17612645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.